Pharmacokinetic parameters for taurocholate, digoxin, pravastatin, and rosuvastatin in rats obtained from the literature and a comparison of rat hepatic clearance in vivo (CLH, vivo) with the hepatic clearance predicted from the uptake clearance in SCRH (CLH, vitro)

CLH, PRBCLH, vivofBCLH, vitro (5 h)CLH, vitro (96 h)
ml · min1 · kg1ml · min1 · kg1ml · min1 · kg1 (CLH, vitro/CLH, vivo ratio)
Taurocholate31.4a0.6b52.30.4c32.1 (0.615)5.65 (0.108)
Digoxin13.3d1.04e12.70.615e12.7 (1.00)7.96 (0.627)
Pravastatin62f1.2f29.4 (0.475)22.5 (0.362)
Rosuvastatin37.6g0.631h59.60.083h16.7 (0.281)5.21 (0.0874)
  • CLH, P, in vivo hepatic clearance based on the plasma concentration assessed as the difference between the total plasma clearance and the renal plasma clearance for each compound; RB, ratio of the blood concentration to the plasma concentration of each compound; fB, unbound fraction of each compound in the total blood.

  • a Data from Hayashi and Sugiyama (2007).

  • b Blood-to-plasma concentration ratio of taurocholate in rats is assumed to be 0.6.

  • c Data from Inoue et al. (1985).

  • d Data from Harrison and Gibaldi (1976).

  • e Data from Liu et al. (2005).

  • f Data from Watanabe et al. (2010).

  • g Data from Kitamura et al. (2008).

  • h Data from Watanabe et al. (2009).